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procarbazine and prednisone) as initial treatment
for Hodgkin lymphoma patients presenting with
severe abnormal liver function
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ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine) remains the most commonly used front-line
therapy for Hodgkin lymphoma. However, atypical and extranodal presentations present challenges to initial therapy,
especially in the presence of renal and liver failure. We hereby present two cases of young male patients with atypical
presentation of Hodgkin lymphoma with severe abnormal liver function. Patients showed excellent response to
cyclophosphamide, etoposide, procarbazine and prednisone (CEPP regimen).
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Hodgkin lymphoma (HL) is characterized by the presence
of Reed-Sternberg cells and lymphadenopathy [1]. There
are two histological types of HL: nodular lymphocyte pre-
dominant and classical HL (cHL). cHL has four entities:
nodular sclerosis, mixed cellularity, lymphocyte depletion,
and lymphocyte-rich. Most patients with HL present with
asymptomatic superficial lymphadenopathy. Extranodal
involvement is uncommon and seen only in 15% of the cases
where it is usually in advanced stages. On the other hand,
hematogenous spread is seen in 5-10% of the cases [2].
Since its first description by Thomas Hodgkin in 1832,
the treatment of HL has significantly changed [3-8].
Hodgkin lymphoma is a highly curable disease in the
current era. Chemotherapy with doxorubicin, bleomycin,
vinblastine and dacarbazine (ABVD regimen) remains
the mainstay of treatment [4,5,9,10]. As per American
Cancer Society’s estimates for HL in the United States,
the 5-year and 10-year survival rates reached 85% and
80%, respectively [11]. However atypical presentations
continue to pose a challenge [2,12].
We report two cases of HL with severe abnormal hepatic
function. Since liver toxicity is a major adverse effect for* Correspondence: delong_liu@nymc.edu
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desired for this group of patients [13,14]. The patients in-
stead received cyclophosphamide, etoposide, procarbazine
and prednisone (CEPP regimen) with remarkable response.Case presentation
Case 1
A 38 year-old male with no significant past medical
history presented with fever for two months. He was ini-
tially treated for bronchitis. Patient soon developed bila-
teral hearing loss and bilateral foot pain. He was started
on doxycycline and prednisone by his local physician
with no improvement. Patient had persistent fever and
developed changes in his mental status. He was admitted
to a local hospital and found to have pancytopenia and ele-
vated transaminases. He was transferred to Westchester
Medical Center for further management. Initial laboratory
data showed acute liver injury (AST: 368 IU/L, ALT:
486 IU/L, alkaline phosphatase: 183 IU/L, total biliru-
bin: 14.6 mg/dL, direct bilirubin: 10.2 mg/dL) and pan-
cytopenia (WBC: 1500/mm3, Hemoglobin: 9.4 g/dL,
Platelets: 59,000/dL). Serologies for hepatitis, Lyme disease,
Ehrlichiosis, Babesiosis, and Rickettsia were all nega-
tive. Cerebrospinal fluid did not reveal anything sig-
nificant. MRI of feet revealed myofascitis and cellulitis
and that of left foot showed myositis. CT scan of theLtd. This is an Open Access article distributed under the terms of the Creative
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pathy. Patient then underwent a liver biopsy. The liver
tissue stained positive for Epstein-Barr virus (EBV) on
immunohistochemistry. The serum EBV DNA level was
49,054 IU/dL. The bone marrow biopsy at that time
revealed severely myelodepleted marrow core with
marked reticulin fibrosis and negative for EBV. Flow
cytometry analysis revealed a mixed population of cells
with polytypic B cells positive for CD20, but no evi-
dence of lymphoma.
Patient was started on cidofovir, an anti-viral medica-
tion, which had to be discontinued later due to worsen-
ing renal failure. Since his symptoms were thought to be
possibly due to a lymphoproliferative disease from EBV
and that flow cytometry was positive for CD20, a trial of
rituximab 375 mg/m2 for one dose was given. After this
single dose of rituximab, his liver enzymes and blood
counts significantly improved. He was subsequently dis-
charged to home. His laboratory data upon discharge were
as follows: WBC 2100/mm3, Hemoglobin 8.1 g/dL, Plate-
lets 329,000/dL, BUN 15 mg/dl, creatinine 1.17 mg/dl,
AST 44 IU/L, ALT 87 IU/L, alkaline phosphatase: 345 IU/
L, total bilirubin: 2.3 mg/dL, direct bilirubin 1.7 mg/dL.
Two months later, he again presented with altered men-
tal status and was found to have elevated transaminases,
persistent fever, pancytopenia and acute kidney injury
(BUN: 136 mg/dL, Cr: 12.6 mg/dL). He was started on
continuous veno-venous hemodialysis (CVVHD) and then
transferred to our institution for further management.
Patient had persistent fever spikes despite being on
broad-spectrum antibiotics. Pertinent laboratory data
during this second admission revealed WBC: 3100/mm3,
platelets: 29,000/dL, Hgb: 9.0 g/dL, AST: 392 IU/dL,
ALT: 312 IU/dL, alkaline Phosphatase: 181 IU/dL, total
bilirubin: 13 mg/dL, direct bilirubin: 10.3 mg/dL, lactate
dehydrogenase: 819 IU/dL, fibrinogen: 141 mg/dL, uric
acid: 8.7 mg/dL, BUN: 86 mg/dL and Cr. 7.9 mg/dL, HIV
status non-reactive and urine myoglobin: 4064 μg/L, EBV
DNA level was 112,073 IU/ml. Repeat bone marrow
biopsy revealed classical Hodgkin lymphoma that was
EBV positive with background trilineage hematopoiesis
and occasional hemophagocytosis. The lymphoma cells
have abundant cytoplasm and mono-, bi- or multinucle-
ated irregular nuclear contour, clumped or smudged chro-
matin and prominent eosinophilic macronucleoli that are
consistent with Reed-Sternberg cells. Immunohistochemi-
cal stains revealed large atypical cells uniformly positive
for CD30 with typical membranous and dot patterns with
focal variable positivity for CD15. The cells were negative
for CD20, CD45, CD3, and ALK1. The atypical cells were
also positive for EBV LMP-1. Thus, the diagnosis of
classical Hodgkin lymphoma, EBV positive, was made.
MRI of the abdomen showed several T2 hyperintense le-
sions scattered throughout the liver and spleen, consistentwith an infiltrative process. Liver biopsy was not done this
time due to low platelet counts.
Given his deranged liver and renal function, ABVD
regimen was not the best choice. Instead, the CEPP regi-
men (cyclophosphamide 600 mg/m2 in 250 ml NS on
day 1 and 8; etoposide 70 mg/m2 in 500 ml NS on Days
1,2,3; procarbazine 60 mg/m2 PO daily on days 1–10,
prednisone 60 mg/m2 daily PO on days 1–10) was used.
The dosages of cyclophosphamide and etoposide were
not reduced for the abnormal liver and renal functions
since the patient was on dialysis, and the dosages of the
two agents were not very high. Patient showed dramatic
response and became afebrile on day 2. His renal and
liver function tests continued to improve and he was
taken off hemodialysis. His total bilirubin came down
from 17 mg/dL before chemotherapy to 2.5 mg/dL upon
discharge. Patient was later discharged to follow with his
local oncologist for further therapy.
Case 2
A 49 year-old male with history of HIV was referred to
Westchester Medical Center for evaluation of persistent
fever and abnormal liver function tests (LFT). He pre-
sented with complaints of recurrent episodes of high
fevers, chills, night sweats, fatigue, itchiness for about
3 months. He also reported decreased appetite and
weight loss of 25 lb. in the past year. Patient was seen as
an outpatient by his Infectious Disease doctor and was
found to have transaminitis and elevated alkaline phos-
phatase. Initially, it was thought that deranged hepatic
tests were induced by Stribild, a combination pill of elvi-
tegravir, cobicistat, emtricitabine, and tenofovir diso-
proxil fumarate for antiretroviral therapy. Stribild was
thus discontinued. However, his abnormal liver function,
fever, and weight loss were not improving and patient
was referred for further evaluation. Clinically, the patient
had no palpable lymphadenopathy nor hepatosplenome-
galy. Initial laboratory data showed acute liver injury
(AST: 359 IU/L, ALT: 437 IU/L, alkaline phosphatase:
2137 IU/L, total bilirubin: 2.5 mg/dL). A CBC showed
WBC: 3500/mm3, Hemoglobin: 12.8 g/dL, Platelets:
339,000/dL. EBV DNA level was 1611 copies/ml. HIV
status: CD 4 count 136 cells/uL, HIV −1 RNA level was < 20
copies/ml and <1.30 Log copies/ml. Hepatitis A, B, C, and
CMV as well as autoimmune panel for anti-mitocondrial
and anti-smooth muscle antibodies were all negative.
CT scan of the chest, abdomen and pelvis revealed a
normal-sized liver, mild splenomegaly of 14.7 cm, and
retroperitoneal lymphadenopathy (LN) with the largest
LN measuring 2.5 cm.
Patient then underwent a liver biopsy which was nega-
tive for infiltrative disease or granulomas. Immunostaining
for EBV and HSV- 1/2 showed negative results. Due
to scattered apoptosis and bile stasis related damages,
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injury was raised, with no overt evidence of lymphoma.
His laboratory data upon discharge was as follows: AST
302 IU/L, ALT 391 IU/L, alkaline phosphatase: 1871 IU/L,
total bilirubin: 2.1 mg/dL, direct bilirubin 1.5 mg/dL.
On subsequent outpatient follow-up, he was found to
have worsening anemia, LFT, and persistent fever. The
patient was admitted to hospital again for re-evaluation.
Pertinent laboratory data during this admission revealed
WBC: 3700/mm3, Hgb: 7.7 g/dL platelets: 226,000/dL,
AST: 99 IU/L, ALT: 94 IU/L, alkaline phosphatase:
1558 IU/L, total bilirubin: 5.5 mg/dL, direct bilirubin:
4.1 mg/dL, LDH: 271 IU/L, Na :129 mEq/L, BUN/Cr:
11 mg/dL and 0.61 mg/dL, HIV status: CD4 count 57
cells/uL, HIV −1 RNA level < 20 copies/ml and <1.30
Log copies/ml and EBV DNA level was 5545 copies /ml.
All blood cultures including bacterial, fungal and AFB as
well as serological investigations for fungal and viral
(with exception of EBV) panels were negative. Patient
continued to be febrile despite administration of broad
spectrum antibiotics.
A bone marrow biopsy was done. Pathology showed
large atypical cells. Occasional large bi-nucleated cells
with abundant amphophilic cytoplasm, prominent large
nucleoli consistent with classic Reed-Sternberg cells
were seen. Immunohistochemical stains showed that the
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morphologic and immunophenotypic findings were con-
sistent with involvement of the marrow by classical
Hodgkin lymphoma.
Pathology from a repeat liver biopsy revealed foci of
large atypical cells with large, mono or bi-lobated nuclei
with abundant amount of cytoplasm, irregular nuclear
contour, and prominent large nucleoli. The surrounding
liver parenchyma was unremarkable. Immunohistochemical
study showed that the large atypical cells were positive for
CD30 and EBV, but negative for CD45, CD15, CD3 and
CD20. CMV, Gram stains, PAS and AFB stains were nega-
tive. Taken together, the findings were suggestive of involve-
ment of liver by Hodgkin lymphoma.
This patient was diagnosed to have classical Hodgkin
lymphoma, stage IVb.
A CT scan of the chest, abdomen and pelvis showed
interval increase in the size of liver (up to 24 cm) and
spleen (up to 16 cm) with no focal hepatic or splenic
lesion. Stable mediastinal, retroperitoneal and external
iliac chain lymphadenopathy was seen.
Given his markedly abnormal liver function, the
ABVD regimen was deemed not to be the best choice.
Instead, the CEPP regimen was administered.
Patient showed a rapid response and became afebrile on
day 2 of chemotherapy. His LFTs continued to improve.t
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1558 U/L before chemotherapy were down to 2.2 mg/dL
and 835 U/L respectively upon discharge on day 10 of the
course. On outpatient follow-up, the LFTs continued to im-
prove, and became virtually normal (AST: 35 IU/L, ALT:
52 IU/L, alkaline phosphatase: 394 IU/L, total bilirubin:
0.5 mg/dL). The patient had no further fever, and regained
weight. The patient became negative on PET/CT scan. He
appeared to have achieved unconfirmed complete remission.
He has returned to work and started ABVD for further
treatment. He remained in clinical remission and was com-
pleting the course of ABVD therapy at the last follow-up.
Discussion
In comparison with extranodal non-Hodgkin’s lymphoma,
extranodal HL is uncommon [2]. There are very few case
reports for acute liver failure at the initial presentation
[15-19] (Table 1). In one large series of 421 consecutive
patients with HL, only six patients (1.4%) had liver abnor-
malities and no palpable lymphadenopathy. The diagnosis
was made through liver biopsy [16]. In 2010, a case of a
20 year-old boy was reported to have similar presentation.
However, he was managed only with intravenous anti-
biotics and he died within 25-days of admission [19]. In
another case report from Chile, a 64 year-old lady pre-
sented with jaundice and malaise. She was diagnosed to
have HL, mixed cellularity type. ABVD was avoided be-
cause of her hepatic involvement. Gemcitabine, cisplatin
and dexamethasone were given with favorable results [20].
There was another case of a 50 year-old man presented
with primary bowel involvement of HL with cholestatic
liver function abnormality and renal failure. He was
managed surgically followed by chemotherapy. They used
nitrogen mustard and prednisone with the omission of
vincristine and procarbazine. However the patient suc-
cumbed to pneumonia and other complications [18].
The current cases had severe abnormal liver function
and unusual clinical courses. The diagnosis of cHL was
confirmed for both patients on second hospital admis-
sion. EBV infection in HL is common [21-25]. Hepatic
involvement is seen at presentation in 6-20% of the HL
patients. The liver involvement is usually diffuse or infil-
trative with patchy, irregular infiltrates originating in the
portal areas. Therapy options and clinical data are very
limited for HL in this type of patients [7,13,14,26,27]. As
most of the conventional chemotherapy regimens could
not be used in these cases, we used CEPP regimen based
on prior experience with non-Hodgkin lymphoma (NHL)
[28]. To our knowledge, this is the first report on the use
of CEPP for initial treatment of HL.
Conclusion
In conclusion, CEPP should be favored as an alternative regi-
men for selected HL patients who can not receive frontlinetreatment options like ABVD or other doxorubicin-containing
regimen. It is unclear at this time whether patients should
receive more cycles of CEPP or switch to ABVD regimen
as further therapy. Brentuximab is used for CD30+ HL [3].
Novel agents should be studied for patients with Hodgkin
lymphoma [29-34]. Clearly, more data are needed for the
treatment of atypical cases of HL in this report.
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